Background: Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory arthropathy-associated with psoriasis. T helper 17 pathway has been shown to play an important role in PsA. Objectives: In this study, we aimed to investigate concentrations of TH17 pathway cytokines such as IL-17, IL-22 and IL-23 in psoriasis (PsO) with/and without structural bone damage and psoriatic arthritis (PsA), and their relationship with disease activity and clinical findings. Methods: A total number of 74 patients, 24 patients with PsA (mean age 57.5±11.37; 13 women, 11 men) and 25 patients with PsO and structural bone damage (mean age 49±13.92; 11 women, 14 men) and 25 patients with PsO and no structural bone damage (mean age 41±16.77; 7 women, 18 men), were recruited from the Department Internal Medicine 3 of the University of Erlangen-Numberg. Both PsO and PsA patients were evaluated according to the CASPAR criteria. Demographic and disease specific variables were recorded. Bone architecture of the metacarpal heads II and III were assessed by highresolution peripheral quantitative computed tomography (HR-pQCT, XtremeCT, Scanco, Switzerland). Disease activity was assessed with Disease Activity Score (DAS28). Psoriatic skin and nail disease activity were measured by the PASI. Results: The ages of the patients in the three groups were similar. IL-17A concentrations were significantly differed between the groups (p=0.000). However, for other cytokines there was no difference between PsA and PsO groups. Serum levels of IL-17A were significantly correlated to patient pain of VAS (r=-0.318, p=0.06), VAS patient global assessment (r=0.272, p=0.021), DAS28 (r=-0.394, p=0.001) and PASI (r=0.519, p=0.000) in PsA and PSO. PASI score were also positively correlated with IL23 (r=-0.286, p=0.015) and S100A8 (r=0.298, p=0.011). Conclusions: IL-17A seems to play an important role in development of PsA and bone damage in PsO. This role should be elucidated by further and larger clinical studies.
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Conclusions:
In pts treated with secukinumab 300 or 150mg, the five individual components related to DAPSA REM were <1 in contrast with other disease states and were sustained through Wk 104. DAPSA REM was associated with significantly greater improvement in physical function, health related quality of life and fatigue indicating that it is an important target to be achieved and sustained in PsA pts. Background: Disease Activity Index for Psoriatic Arthritis (DAPSA) is a validated tool to measure disease activity states, focussing on peripheral joint involvement in psoriatic arthritis (PsA), and can be used to assess targets such as remission (REM) or low disease activity (LDA). Objectives: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, significantly improved American College of Rheumatology responses vs. placebo at Week (Wk) 24 that were sustained through Wk 104 in active PsA patients (pts) in the FUTURE 2 study 2 . This post-hoc exploratory analysis assessed DAPSA states through Wk 104. Methods: In total, 397 active PsA pts were randomised to subcutaneous (s.c) secukinumab (300, 150 or 75mg) or placebo at baseline and Wks 1, 2, 3 and 4, and every 4 wks (q4w) thereafter. Placebo pts were re-randomised to secukinumab 300 or 150mg s.c q4w from Wk 16 or 24, depending on Wk 16 clinical response. DAPSA was derived as the sum of five variables: tender joint and swollen joint counts (TJC 68 and SJC 66); pt global and pain assessed on a 10cm visual analogue scale; and C-reactive protein levels (mg/dl) with validated cut-offs to indicate REM (≤4), LDA (>4 and ≤14), moderate disease activity (MDA; >14 and ≤28) and high disease activity (HDA; >28). DAPSA was assessed in the overall population and in pts stratified by prior anti-tumour necrosis factor (anti-TNF) therapy use (anti-TNF-naïve vs. inadequate response/intolerance to these agents [anti-TNF-IR]) and time since first PsA diagnosis (≤2 vs. >2 years) using observed data. Only data for secukinumab 300 and 150mg (approved doses) are reported. Results: Baseline demographics and clinical characteristics were similar across treatment groups and previously reported.
3 DAPSA score at baseline (mean [SD]) was 42.0 (17.4), 46.8 (24.3) and 44.9 (25.3) in the secukinumab 300mg, 150mg and placebo groups, respectively. In the overall population, at Wk 16, REM was achieved in 14/97 (14.4%) with secukinumab 300mg and 10/100 (10%) with secukinumab 150mg vs. placebo 4/87 (4.6%); LDA in 27/97 (27.8%) and 34/100 (34%) vs. 12/87 (13.8%), respectively. REM or LDA were sustained through Wk 104 with secukinumab 300 and 150mg (55/ and by time since diagnosis (≤2 vs. >2 years) for secukinumab 300 and 150mg is presented in the figure. Conclusions: In the overall population, a higher proportion of pts treated with secukinumab at Wk 16 achieved DAPSA REM than those treated with placebo, with REM and LDA sustaining through Wk 104. At Wk 16, a higher proportion of anti-TNF-naïve pts treated with secukinumab achieved and sustained DAPSA REM than anti-TNF-IR pts and a higher proportion of pts with early diagnosis (≤2 years) achieved DAPSA REM vs. pts diagnosed later (>2 years). McInnes, et al. Lancet 2015; 386:1137-46 . Disclosure of Interest: J. Smolen Grant/research support from: AbbVie, Janssen, Eli Lilly, MSD, Pfizer, Roche, Amgen, AstraZeneca, Astro, Celgene, Celltrion, GSK, ILTOO, Medimmune, Novartis-Sandoz, Pfizer, Samsung, Sanofi and UCB., Consultant for: AbbVie, Janssen, Eli Lilly, MSD, Pfizer, Roche, Amgen, AstraZeneca, Astro, Celgene, Celltrion, GSK, ILTOO, Medimmune, Novartis-Sandoz, Pfizer, Samsung, Sanofi and UCB., I. McInnes Grant/research support from: AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB., Consultant for: AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB., Speakers bureau: AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB., T. Kvien Consultant for: AbbVie, Biogen, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Epirus, Janssen, Merck-Serono, MSD, Mundipharma, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz and UCB., Speakers bureau: AbbVie, Biogen, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Epirus,
